Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080014 | 0.91 | CA1 (0.38) | NQO2CA1CA2TDP1STK17B | |
| SCHEMBL6590869 | 0.91 | NQO2 (0.40) | NQO2CA1CA2TDP1STK17B | |
| SCHEMBL6590517 | 0.82 | CA1 (0.38) | NQO2CA1CA2TDP1STK17B | |
| SCHEMBL6080532 | 0.82 | NQO2 (0.42) | NQO2CA1CA2TDP1STK17B | |
| SCHEMBL6080865 | 0.81 | CYP4A11 (0.43) | NQO2 | |
| SCHEMBL6080040 | 0.80 | NQO2 (0.47) | NQO2CA1CA2BRD4CA12 | |
| SCHEMBL6080677 | 0.78 | NQO2 (0.38) | NQO2CA1CA2TDP1STK17B | |
| SCHEMBL5200513 | 0.74 | CA1 (0.47) | NQO2CA1CA2TDP1CA12 | |
| SCHEMBL6080612 | 0.73 | NQO2 (0.44) | NQO2CA1CA2BRD4CA12 | |
| SCHEMBL6602769 | 0.72 | NQO2 (0.43) | NQO2CA1CA2TDP1STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | NQO2 2/4885CA1 2702/4885CA2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.